文献

J-GLOBAL ID：201202245993058610   整理番号：12A1340597

重度のグラム陰性感染の治療に対するピリドンメチルスルホンヒドロキサメートLpxC阻害剤

Pyridone Methylsulfone Hydroxamate LpxC Inhibitors for the Treatment of Serious Gram-Negative Infections

著者 (37件)： MONTGOMERY Justin I. (Pfizer Worldwide Res. and Dev., Connecticut, USA) ,  BROWN Matthew F. (Pfizer Worldwide Res. and Dev., Connecticut, USA) ,  REILLY Usa (Pfizer Worldwide Res. and Dev., Connecticut, USA) ,  PRICE Loren M. (Pfizer Worldwide Res. and Dev., Connecticut, USA) ,  ABRAMITE Joseph A. (Pfizer Worldwide Res. and Dev., Connecticut, USA) ,  ARCARI Joel (Pfizer Worldwide Res. and Dev., Connecticut, USA) ,  BARHAM Rose (Pfizer Worldwide Res. and Dev., Connecticut, USA) ,  CHE Ye (Pfizer Worldwide Res. and Dev., Connecticut, USA) ,  CHEN Jinshan Michael (Pfizer Worldwide Res. and Dev., Connecticut, USA) ,  CHUNG Seung Won (Pfizer Worldwide Res. and Dev., Connecticut, USA) ,  COLLANTES Elizabeth M. (Pfizer Worldwide Res. and Dev., Connecticut, USA) ,  DESBONNET Charlene (Pfizer Worldwide Res. and Dev., Connecticut, USA) ,  DOROSKI Matthew (Pfizer Worldwide Res. and Dev., Connecticut, USA) ,  DOTY Jonathan (Pfizer Worldwide Res. and Dev., Connecticut, USA) ,  ENGTRAKUL Juntyma J. (Pfizer Worldwide Res. and Dev., Connecticut, USA) ,  HARRIS Thomas M. (Pfizer Worldwide Res. and Dev., Connecticut, USA) ,  HUBAND Michael (Pfizer Worldwide Res. and Dev., Connecticut, USA) ,  KNAFELS John D. (Pfizer Worldwide Res. and Dev., Connecticut, USA) ,  LEACH Karen L. (Pfizer Worldwide Res. and Dev., Connecticut, USA) ,  LIU Shenping (Pfizer Worldwide Res. and Dev., Connecticut, USA) ,  MARFAT Anthony (Pfizer Worldwide Res. and Dev., Connecticut, USA) ,  MCALLISTER Laura (Pfizer Worldwide Res. and Dev., Connecticut, USA) ,  MCELROY Eric (Pfizer Worldwide Res. and Dev., Connecticut, USA) ,  MENARD Carol A. (Pfizer Worldwide Res. and Dev., Connecticut, USA) ,  MITTON-FRY Mark (Pfizer Worldwide Res. and Dev., Connecticut, USA) ,  MULLINS Lisa (Pfizer Worldwide Res. and Dev., Connecticut, USA) ,  NOE Mark C. (Pfizer Worldwide Res. and Dev., Connecticut, USA) ,  O’DONNELL John (Pfizer Worldwide Res. and Dev., Connecticut, USA) ,  OLIVER Robert (Pfizer Worldwide Res. and Dev., Connecticut, USA) ,  PENZIEN Joseph (Pfizer Worldwide Res. and Dev., Connecticut, USA) ,  PLUMMER Mark (Pfizer Worldwide Res. and Dev., Connecticut, USA) ,  SHANMUGASUNDARAM Veerabahu (Pfizer Worldwide Res. and Dev., Connecticut, USA) ,  THOMA Christy (Pfizer Worldwide Res. and Dev., Connecticut, USA) ,  TOMARAS Andrew P. (Pfizer Worldwide Res. and Dev., Connecticut, USA) ,  UCCELLO Daniel P. (Pfizer Worldwide Res. and Dev., Connecticut, USA) ,  VAZ Alfin (Pfizer Worldwide Res. and Dev., Connecticut, USA) ,  WISHKA Donn G. (Pfizer Worldwide Res. and Dev., Connecticut, USA)
資料名： Journal of Medicinal Chemistry  (Journal of Medicinal Chemistry)
巻： 55  号： 4  ページ： 1662-1670  発行年： 2012年02月23日 
JST資料番号： D0102A  ISSN： 0022-2623  CODEN： JMCMAR  資料種別： 逐次刊行物 (A)
発行国： アメリカ合衆国 (USA)  言語： 英語 (EN)

タイトルに関連する用語 (3件)： 感染 ,  治療 ,  阻害剤